EPRO | Jotup

Axiom Exhibiting at 14th Annual SCOPE: Summit for Clinical Ops Executives

Retrieved on:

Monday, February 6, 2023

Axiom, Booth, EDC, Attention, SCOPE, EPRO, Suite, Clinical trial, Metric, Clinical data management, Pharmaceutical industry

The 14th Annual SCOPE Summit brings together key industry leaders to connect and discuss solutions in all aspects of clinical trial innovation, planning, management and operations.

Key Points:

The 14th Annual SCOPE Summit brings together key industry leaders to connect and discuss solutions in all aspects of clinical trial innovation, planning, management and operations.
The conference will bring together pharmaceutical and biotech experts to connect and explore solutions to current challenges associated with clinical trials.
“Axiom’s Fusion eClinical Suite provides clients and research centers with a single point of access to all of their study data and clinical operational needs.
Axiom Fusion eClinical Suite enables small to medium life science companies to dramatically change how you manage US and global clinical studies.

Suvoda 2022 Clinical Trials Surge 20% as it Expands Offerings to Include eConsent and eCOA

Retrieved on:

Tuesday, January 17, 2023

PHILADELPHIA, Jan. 17, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,000 clinical trials in 2022 as study deployments surged nearly 20%, a strong indicator that the company's practical approach to innovation is being embraced by trial sponsors and CROs. Click to tweet.

Key Points:

Suvoda's expanded clinical trial offerings in 2022 were designed organically to work seamlessly on a single platform, and include important features that sponsors need to quickly and reliably conduct trials.
New products and features include:
eConsent – Suvoda eConsent, which became generally available in May, offers a simplified approach to digitizing the consent management process.
Electronic clinical outcome assessment (eCOA) – Suvoda eCOA seeks to tackle inefficiencies common in traditional eCOA products, such as gaps in overall delivery and execution quality, time-consuming translations and localization processes, and logistics related to device management.
"Trial sponsors and CROs have told us they need new approaches to global clinical trials with patients at the center of the studies, and we have listened," said Jagath Wanninayake, CEO of Suvoda.

Suvoda 2022 Clinical Trials Surge 20% as it Expands Offerings to Include eConsent and eCOA

Retrieved on:

Tuesday, January 17, 2023

PHILADELPHIA, Jan. 17, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, surpassed 1,000 clinical trials in 2022 as study deployments surged nearly 20%, a strong indicator that the company's practical approach to innovation is being embraced by trial sponsors and CROs. Click to tweet.

Key Points:

Suvoda's expanded clinical trial offerings in 2022 were designed organically to work seamlessly on a single platform, and include important features that sponsors need to quickly and reliably conduct trials.
New products and features include:
eConsent –Suvoda eConsent, which became generally available in May, offers a simplified approach to digitizing the consent management process.
Electronic clinical outcome assessment (eCOA) --Suvoda eCOA seeks to tackle inefficiencies common in traditional eCOA products, such as gaps in overall delivery and execution quality, time-consuming translations and localization processes, and logistics related to device management.
"Trial sponsors and CROs have told us they need new approaches to global clinical trials with patients at the center of the studies, and we have listened," said Jagath Wanninayake, CEO of Suvoda.

Intero Welcomes Darrell Johnson as Vice President and Co-Managing Officer of Intero Gardnerville

Retrieved on:

Wednesday, January 18, 2023

Intero, a Berkshire Hathaway affiliate and wholly owned subsidiary of HomeServices of America, Inc., is proud to announce the appointment of Darrell “DJ” Johnson as Vice President and Co-Managing Officer of the Gardnerville office.

Key Points:

Intero, a Berkshire Hathaway affiliate and wholly owned subsidiary of HomeServices of America, Inc., is proud to announce the appointment of Darrell “DJ” Johnson as Vice President and Co-Managing Officer of the Gardnerville office.
He is running the office with Jen Almeida, who took over the co-leadership role from Teddy Carlson-McKone in Q3 of 2022.
“Dennis started Intero Gardnerville with Teddy Carlson-McKone in 2010 and I speak for all of us when I say we are thankful to both of them for building such a successful business and office culture there,” said Brian Crane, Chief Executive Officer of Intero.
"I love my local community and I love working with buyers and sellers to achieve their real estate goals,” said Darrell Johnson, Vice President and Co-Managing Officer of the Gardnerville office.

Investment in Site Enablement to Accelerate Research Grows 300% - Florence Healthcare Releases State of Clinical Trial Technology Report

Retrieved on:

Wednesday, January 11, 2023

Florence Healthcare™, a clinical research technology company, has released its annual State of Clinical Trial Technology Report .

Key Points:

Florence Healthcare™, a clinical research technology company, has released its annual State of Clinical Trial Technology Report .
Over four hundred clinical research sites, sponsors, and Contract Research Organizations (CROs) responded to the survey about how they plan to invest in software for their 2023 studies.
“The survey responses make it clear that 2023 is the year of Site Enablement,” said Catherine Gregor, Chief Clinical Trial Officer for Florence Healthcare.
“It’s clear that trial sites are gaining power over research technology decisions,” said Ryan Jones, CEO of Florence Healthcare.

Datacubed Health, a Sterling Partners Portfolio Company, Achieves Impressive 150% YOY Growth

Retrieved on:

Tuesday, December 20, 2022

Clinical trial, Translation, Rigidity, Televisit, COVID-19, Sterling, Health, EPRO, Cros, Patient engagement in Canada, Growth, Clinical data management, Entrepreneurship, Investment, Guest appearance, Datacube Inc., Medicine, Fine chemical, Pharmaceutical industry

Brooklyn, New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Datacubed Health (“Datacubed”), a digital health technology company that supports hybrid and decentralized clinical trials, and Sterling Partners (“Sterling”), a prominent investment management firm, announced December 20, 2022, substantial year-over-year growth.

Key Points:

Brooklyn, New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Datacubed Health (“Datacubed”), a digital health technology company that supports hybrid and decentralized clinical trials, and Sterling Partners (“Sterling”), a prominent investment management firm, announced December 20, 2022, substantial year-over-year growth.
Following its initial investment in 2020, Sterling has continued to support Datacubed.
At its founding, Datacubed was rooted in behavioral science and offered a gamified ePRO solution designed to boost patient engagement.
Steven Taslitz, Co-Founder and Chairman of Sterling Partners, said, “We believe the industry is at an inflection point.

Insights on the Virtual Clinical Trials Global Market to 2027 - Key Players Include Dassault Systemes, Medable, Science 37 and THREAD

Retrieved on:

Thursday, December 22, 2022

The virtual clinical trials market is one of the innovative approaches for traditional clinical trials, through remote monitoring and more patient-centric approaches.

Key Points:

The virtual clinical trials market is one of the innovative approaches for traditional clinical trials, through remote monitoring and more patient-centric approaches.
The COVID-19 pandemic is the significant factor that shifted the traditional clinical trials approach to the virtual clinical trials market.
The market players and the companies pioneer in clinical trials activities understand that decentralization in clinical trials is the future of the clinical trials space.
THREAD offers a unique, innovative, and highly advanced decentralized clinical trial platform in the virtual clinical trials market.

Sure Med Compliance Announces Strategic Engagement with Former U.S. "Drug Czar" & DEA Head

Retrieved on:

Thursday, December 15, 2022

EPRO, Physician, Drug Enforcement Administration, Senate, Drug, ONDCP, Patient, White House, Pain, Dhillon, DEA, Office of National Drug Control Policy, Pain management, United, Medical device

MOBILE, Ala., Dec. 15, 2022 /PRNewswire/ -- Sure Med Compliance, a digital health startup focused on curbing the opioid-related overdose epidemic, today announced its engagement of Michael Best Advisors Principals Hon. Jim Carroll and Hon. Uttam Dhillon. Mr. Carroll served as the Director of the White House Office of National Drug Control Policy (ONDCP) (colloquially known as the U.S. "Drug Czar") from 2019 – 2021; Mr. Dhillon served as the Acting Administrator of the Drug Enforcement Administration (DEA) from 2018 – 2020. Both have the distinction of having enjoyed unanimous confirmation by the United States Senate during their extensive careers in federal service.

Key Points:

"Sure Med Compliance was created to equip health care providers with scientifically validated clinical guidance and robust medicolegal protection," Sure Med Compliance CEO John Bowman stated.
"As an early-stage startup, Sure Med Compliance is at an inflection point in their development," Dhillon added.
"I'm excited to work with Sure Med Compliance and assist them in their important mission."
About Sure Med Compliance: Sure Med Compliance is the first and only digital health platform scientifically validated to mitigate risk to both patient and provider in pain management settings.

Vial Welcomes Dr. Rajesh Pahwa, Chief of the Parkinson's and Movement Disorder Division at the University of Kansas Medical Center, to its Central Nervous System Scientific Advisory Board

Retrieved on:

Thursday, November 17, 2022

SAN FRANCISCO, Nov. 16, 2022 /PRNewswire/ -- Vial welcomes Dr. Rajesh Pahwa as a new Central Nervous System (CNS) advisory board member to their Neurology CRO .

Key Points:

SAN FRANCISCO, Nov. 16, 2022 /PRNewswire/ -- Vial welcomes Dr. Rajesh Pahwa as a new Central Nervous System (CNS) advisory board member to their Neurology CRO .
Dr. Pahwa joins fellow Vial scientific board members, Dr. Robert Hauser and Dr. Joseph Jankovic .
On the partnership, Dr. Pahwa shared, "I am delighted to join Vial's scientific advisory board and contribute to the evolution of their Neurology CRO.
Vial operates across multiple therapeutic areas ( Dermatology CRO , Ophthalmology CRO , Oncology CRO , Gastroenterology CRO , Neurology CRO , and Cardiology CRO ).

Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Retrieved on:

Tuesday, November 8, 2022

The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu .

Key Points:

The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu .
FILOSOPHY (FILgotinib Observational Study Of Patient Health-related outcomes), is a prospective, observational, non-interventional cohort Phase 4 study enrolling approximately 1500 patients aged 18 years with moderately to severely active RA across Europe.
Each enrolled patient will be followed for 24 months or until discontinuation of the study, whichever occurs first.
Our first medicine for rheumatoid arthritis and ulcerative colitis is available in the European Union, Norway, Great Britain, and Japan.